Bennett B. Chin, MD

home / authors / bennett-b-chin-md

Articles

Post-Prostatectomy Radiation Therapy: Patient Selection, Timing, Imaging, and Therapy Intensification

Tyler P. Robin, MD, PhD;Paul D. Maroni, MD;Bennett B. Chin, MD;Francisco G. La Rosa, MD;Brandon Bernard, MD, MPH;Thomas J. Pugh, MD

July 15th 2018

A 62-year-old man with prostate adenocarcinoma elected to proceed with radical prostatectomy as definitive management. After his pathology report showed stage IIIB disease, he elected for observation. What happened next?

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.

Published: January 24th 2025 | Updated: February 6th 2025

FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS

Published: September 13th 2024 | Updated: November 25th 2024

Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates

NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.

Published: August 9th 2024 | Updated: August 14th 2024

Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets

Published: June 2nd 2024 | Updated: June 3rd 2024

OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer

Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.

Published: May 6th 2024 | Updated: May 21st 2024

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

Published: April 21st 2021 | Updated: April 21st 2025

How to Radiologically Assess and Follow Response After Treatment of Hepatocellular Carcinoma

Do Not Sell My Personal Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777